These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10066890)

  • 1. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks.
    Senarisoy M; Canturk P; Zencir S; Baran Y; Topcu Z
    Cell Biochem Biophys; 2013 May; 66(1):199-204. PubMed ID: 23161103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
    Capranico G; Binaschi M
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
    Thielmann HW; Popanda O; Gersbach H; Gilberg F
    Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase enzymes as drug targets.
    Guichard SM; Danks MK
    Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase as target for antibacterial and anticancer drug discovery.
    Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
    J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
    Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerases, new targets in cancer chemotherapy.
    Zijlstra JG; de Jong S; de Vries EG; Mulder NH
    Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to topoisomerases poisons.
    Prost S
    Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II.
    Suzuki K; Yahara S; Hashimoto F; Uyeda M
    Biol Pharm Bull; 2001 Sep; 24(9):1088-90. PubMed ID: 11558576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase I poisons and suppressors as anticancer drugs.
    Bailly C
    Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
    Fortune JM; Osheroff N
    Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II inhibitors design: Early studies and new perspectives.
    Swedan HK; Kassab AE; Gedawy EM; Elmeligie SE
    Bioorg Chem; 2023 Jul; 136():106548. PubMed ID: 37094479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iridoids as DNA topoisomerase I poisons.
    Gálvez M; Martín-Cordero C; Ayuso MJ
    J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
    Burden DA; Osheroff N
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):139-54. PubMed ID: 9748545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
    Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
    Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.